Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Frasier
How Artificial Intelligence Helps Power Parkinson’s Research
Parkinson’s researchers are using artificial intelligence (AI) to drive innovations that are helping uncover new biological patterns, reveal how Parkinson’s progresses and identify promising targets for treatment faster than ever before. By analyzing massive, complex datasets, AI is leading to breakthroughs that could fundamentally change how we understand and treat Parkinson’s.
What We Fund: Big Boost to Biomarker Efforts in June, July
The Michael J. Fox Foundation (MJFF) issued dozens of grants over June and July of 2025, including a concerted effort to advance a key prong of MJFF’s strategy – figuring out how to measure the misfolded proteins that are implicated in Parkinson’s progression. This work to develop quantifying seeding amplification assays saw five new projects funded, totaling more than $4 million in research dollars.
Parkinson’s Disease Therapeutics Conference Showcases Progress Toward Better Treatments
In order to make this article easier to read, we’ve included the affiliations of the speakers at the bottom of the article. The Michael J. Fox Foundation (MJFF) hosted the world’s only conference focused entirely on Parkinson’s disease (PD) therapeutics in New York City on October 13.
Research Perspective: Reflecting on the Latest FDA Approvals in Parkinson’s and the Promise Ahead
At The Michael J. Fox Foundation (MJFF), our best barometer of progress in addressing challenges faced by those with Parkinson’s disease has always been new drug approvals. Last week, Kynmobi from Sunovion Pharmaceuticals became the 16th treatment for Parkinson’s approved since 2014. MJFF funded early-stage development of Kynmobi in 2012 and 2014. It’s the second MJFF-enabled therapy to receive regulatory approval. The first, Acorda’s Inbrija, was approved in 2018.
Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's
This interview was conducted by Lauren Pulling, Editor of Neurology Central.
Perspective: Data sharing for discovery
The current rate of drug development for Parkinson's disease is unprecedented, aided by the discovery of genetic targets and by the creative repurposing of drugs from other diseases. Many of these therapies show promise in being able to slow or halt Parkinson's. Clinical trials of these drugs need reliable tools to assist with patient selection and stratification, and to reveal whether the drug is acting on the underlying disease process.
Seminar Call Series Kicks Off with "How Do We Get to Cures?"
Help us speed a cure for the 6 million people worldwide living with Parkinson's. Join our email list to get the latest news and resources directly to your inbox. First Name Last Name Email Zip Code Connection to Parkinson's What Year Were You Diagnosed with PD? Sign Up
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack